Prediction of flare-ups of ulcerative colitis using quantitative immunochemical fecal occult blood test

被引:16
作者
Kuriyama, Motoaki [1 ]
Kato, Jun [1 ]
Takemoto, Koji [1 ]
Hiraoka, Sakiko [1 ]
Okada, Hiroyuki [1 ]
Yamamoto, Kazuhide [1 ]
机构
[1] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gastroenterol & Hepatol, Kita Ku, Okayama 7008558, Japan
关键词
Flare-ups; Immunochemical fecal occult blood test; Inflammatory bowel disease; Prediction; Ulcerative colitis; INFLAMMATORY-BOWEL-DISEASE; ACUTE-PHASE PROTEINS; COLORECTAL-CANCER; PERFORMANCE-CHARACTERISTICS; CHINESE POPULATION; NEOPLASIA; RELAPSE; THERAPY;
D O I
10.3748/wjg.v16.i9.1110
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
AIM: To examine the feasibility of predicting the flare-up of ulcerative colitis (UC) before symptoms emerge using the immunochemical fecal occult blood test (I-FOBT). METHODS: We prospectively measured fecal hemoglobin concentrations in 78 UC patients using the I-FOBT every 1 or 2 mo. RESULTS: During a 20 mo-period, 823 fecal samples from 78 patients were submitted. The median concentration of fecal hemoglobin was 41 ng/mL (range: 0-392500 ng/mL). There were three types of patients with regard to the correlation between I-FOBT and patient symptoms; the synchronous transition type with symptoms (44 patients), the unrelated type with symptoms (19 patients), and the flare-up predictive type (15 patients). In patients with the flare-up predictive type, the values of I-FOBT were generally low during the study period with stable symptoms. Two to four weeks before the flare-up of symptoms, the I-FOBT values were high. Thus, in these patients, I-FOBT could predict the flare-up before symptoms emerged. CONCLUSION: Flare-up could be predicted by I-FOBT in approximately 20% of UC patients. These results warrant periodical I-FOBT in UC patients. (C) 2010 Baishideng. All rights reserved.
引用
收藏
页码:1110 / 1114
页数:5
相关论文
共 36 条
[1]   Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics [J].
Allison, James E. ;
Sakoda, Lori C. ;
Levin, Theodore R. ;
Tucker, Jo P. ;
Tekawa, Irene S. ;
Cuff, Thomas ;
Pauly, Mary Pat ;
Shlager, Lyle ;
Palitz, Albert M. ;
Zhao, Wei K. ;
Schwartz, J. Sanford ;
Ransohoff, David F. ;
Selby, Joseph V. .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2007, 99 (19) :1462-1470
[2]  
Allison JE, 1998, ALIMENT PHARM THERAP, V12, P1
[3]   A comparison of fecal occult-blood tests for colorectal-cancer screening [J].
Allison, JE ;
Tekawa, IS ;
Ransom, LJ ;
Adrain, AL .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (03) :155-159
[4]   ACUTE PHASE PROTEINS IN CHRONIC INFLAMMATORY BOWEL-DISEASE IN CHILDHOOD [J].
CAMPBELL, CA ;
WALKERSMITH, JA ;
HINDOCHA, P ;
ADINOLFI, M .
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 1982, 1 (02) :193-200
[5]   Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease [J].
Costa, F ;
Mumolo, MG ;
Ceccarelli, L ;
Bellini, M ;
Romano, MR ;
Sterpi, C ;
Ricchiuti, A ;
Marchi, S ;
Bottai, M .
GUT, 2005, 54 (03) :364-368
[6]   Immunological tests to monitor inflammatory bowel disease - Have they delivered yet? [J].
Cronin, CC .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 1998, 93 (03) :295-297
[7]   Mechanisms of disease: Acute-phase proteins and other systemic responses to inflammation [J].
Gabay, C ;
Kushner, I .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (06) :448-454
[8]  
Greenberg PD, 2000, AM J GASTROENTEROL, V95, P1331
[9]   Randomised controlled trial of faecal-occult-blood screening for colorectal cancer [J].
Hardcastle, JD ;
Chamberlain, JO ;
Robinson, MHE ;
Moss, SM ;
Amar, SS ;
Balfour, TW ;
James, PD ;
Mangham, CM .
LANCET, 1996, 348 (9040) :1472-1477
[10]   Serum concentrations of orosomucoid: Improved decision-making for tapering prednisolone therapy in patients with active inflammatory bowel disease? [J].
Kjeldsen, J ;
Lauritsen, K ;
DeMuckadell, OBS .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1997, 32 (09) :933-941